<DOC>
	<DOCNO>NCT02452372</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ALN-AS1 AIP patient well characterize pharmacokinetics ( PK ) pharmacodynamics ( PD ) ALN-AS1 AIP patient .</brief_summary>
	<brief_title>A Phase 1 Study ALN-AS1 Patients With Acute Intermittent Porphyria ( AIP )</brief_title>
	<detailed_description />
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Porphyria , Acute Intermittent</mesh_term>
	<criteria>Parts A B Diagnosis AIP Urine PBG Screening indicate patient high excreter No clinically significant health concern Women child bear potential must negative pregnancy test , nursing , use effective contraception Willing provide write informed consent willing comply study requirement . Porphyria attack within 6 month screen Started new prescription medication within 3 month screen Clinically significant abnormal laboratory result Received investigational agent within 90 day first dose study drug followup another clinical study History multiple drug allergy intolerance subcutaneous injection Part C Diagnosis AIP Patient experience porphyria attack take medication prevent attack recently No clinically significant health concern Women child bear potential must negative pregnancy test , nursing , use effective contraception Willing provide write informed consent willing comply study requirement . Stared new prescription medication within 3 month screen Clinically significant abnormal laboratory result Received investigational agent within 90 day first dose study drug followup another clinical study History multiple drug allergy intolerance subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Porphyria</keyword>
	<keyword>AIP</keyword>
</DOC>